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rch 3, 2013.he purpose of this study was to investigate the associations of traditional risk factors and longitudinal
measures of human immunodeﬁciency virus (HIV) disease severity with risk of incident atrial ﬁbrillation (AF) in
a contemporary cohort of HIV-infected individuals.Background Cardiovascular disease is common in HIV-infected persons; however, the most common cardiac arrhythmia, AF, has
not been adequately studied in this population.Methods We studied a national sample of 30,533 HIV-infected veterans followed in the Veterans Affairs HIV Clinical Case
Registry from 1996 to 2011. We examined the independent associations of demographic characteristics, time-
updated comorbidities, and time-updated clinical measurements including CD4þ cell count and viral load with the
outcome of incident AF using proportional hazards regression for multivariable analysis.Results Over a median follow-up of 6.8 years, 780 (2.6%) patients developed AF. After multivariable adjustment for
traditional risk factors, a lower CD4þ cell count (<200 compared with >350 cells/mm3; hazard ratio [HR]: 1.4; 95%
conﬁdence interval [CI]: 1.1 to 1.8; p ¼ 0.018) and higher viral load (>100,000 compared with <500 copies/ml;
HR: 1.7; 95% CI: 1.2 to 2.4; p ¼ 0.002) were independently associated with increased risk of incident AF. Additional
risk factors independently associated with risk of AF included older age, White race, coronary artery disease,
congestive heart failure, alcoholism, proteinuria, reduced kidney function, and hypothyroidism.Conclusions In a large HIV-infected cohort, markers of HIV disease severity represented by low CD4þ cell count and high viral
load, assessed by multiple time-updated measures, were independently associated with development of AF.
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tinues to be a major public health problem in the United
States, affecting over 1.1 million people (1). Since the advent
of highly active antiretroviral therapy, the natural history of
HIV has drastically changed, as HIV mortality, acquired
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2; revised manuscript received January 30, 2013,increased life expectancy (2). However, in the aging HIV-
infected population, coronary artery disease, peripheral
vascular disease, and congestive heart failure have emerged as
growing cardiovascular health problems associated with
signiﬁcant morbidity and mortality (3,4).
The most common cardiac arrhythmia, atrial ﬁbrillation
(AF), is also associated with considerable morbidity such as
stroke and heart failure (5), and has emerged as a growing
problem in the aging U.S. population (6). HIV infection is
known to be an independent risk factor for atherosclerosis and
stroke (7,8), and similar mechanisms may be involved in the
genesis of atherosclerotic cardiovascular disease and AF. To
our knowledge, no previous study has examined the incidence
of AF in HIV-infected persons despite shared risk factors
associated with both atherosclerosis and AF. Additionally, no
study has evaluated whether advanced or uncontrolled HIV
infection is associated with the risk of developing AF.
We analyzed data from the Department of Veterans
Affairs (VA) HIV Clinical Case Registry, a national registry
Abbreviations
and Acronyms
AIDS = acquired immune
deﬁciency syndrome
AF = atrial ﬁbrillation
BMI = body mass index
CI = conﬁdence interval
eGFR = estimated
glomerular ﬁltration rate
HIV = human
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2289of HIV-infected veterans that captures patient demographic
and clinical information, healthcare utilization, and out-
comes. In this large population of HIV-infected patients,
we examined the incidence of AF to determine the burden
of AF in HIV-infected persons and evaluate the strength
of known AF risk factors in this population. In order to
investigate a potential association of HIV disease severity
with the risk of developing AF, we assessed whether a lower
CD4þ cell count and a higher HIV RNA viral load were
associated with an increased risk of developing AF inde-
pendent of traditional risk factors.immunodeﬁciency virus
HR = hazard ratio
IQR = interquartile range
VA = Veterans AffairsMethods
Data source. The VA HIV Clinical Case Registry was
created to allow VA monitoring of healthcare utilization for
all HIV-infected veterans. The registry contains all demo-
graphic, clinical, laboratory, pharmacy, utilization, and vital
status information entered into the VA electronic medical
record for HIV-infected persons (9). We investigated the
association between HIV severity indices (CD4þ cell count
and viral load), patient demographics, comorbidities, and
clinical measures with development of AF in this large,
national sample of HIV-infected veterans. The Veterans
Health Administration offers low-cost, comprehensive
medical care to U.S. veterans with a broad, nationwide
geographic scope (10).
Study population. We identiﬁed 30,820 patients diag-
nosed with HIV infection between January 1996 and January
2011 in the VA HIV Clinical Case Registry. Among these
individuals, we excluded 90 patients with prevalent AF at
entry and 197 patients who died within 1-month follow-up,
leaving 30,533 patients for our analysis. Patients entered the
cohort at the time of their ﬁrst known documentation of
HIV diagnosis and were censored at their ﬁrst episode of
AF, death, or last date of follow-up (January 2011).
Outcomes. The primary outcome was time from study
entry to incident AF diagnosis, deﬁned by database coding
for ﬁrst inpatient hospitalization or outpatient diagnosis of
AF. The primary AF outcome comprised a diagnosis of AF
or atrial ﬂutter, speciﬁed by International Classiﬁcation of
Diseases-Ninth Edition (ICD-9) codes 427.31 and 427.32,
respectively. Patients were classiﬁed as either having AF or
atrial ﬂutter based on the ﬁrst arrhythmia diagnosed when
censored. Previous studies have demonstrated a high sensi-
tivity and speciﬁcity (95% and 99%, respectively) for the
diagnosis of AF after extensive duplicative review of medical
records to verify the diagnosis and conﬁrm that the AF was
new onset (11).
Primary predictors. The primary predictors of interest were
serological measures of HIV disease severity, including CD4þ
cell count expressed in cells/mm3 and viral load expressed in
RNA copies/ml. CD4þ cell count and viral load were treated
as time-varying predictors, updated over time with the last
value carried forward method. This method has been used
in prior studies examining immunologic and virologicalpredictors of HIV-related disease,
and avoids misclassiﬁcation due
to reliance upon a single mea-
surement at a single ﬁxed point
in time (12,13). For purposes of
analysis, we divided CD4þ cell
count and viral load into clinical-
ly meaningful ordinal categories,
from low to high, as follows:
CD4þ cell count <200, 200 to
350, or >350 cells/mm3 and viral
load <500, 500 to 29,999, 30,000
to 100,000, and >100,000 RNA
copies/ml.
Covariates. We also investigat-
ed traditional demographic char-
acteristics and comorbidities known to be associated with
AF in our multivariate models to assess for their strength of
association and to adjust for confounding in our multivariable
models. Age was categorized by decades around the mean age
of the cohort, as well as by both extremes of younger (<35
years) and older (65 years) patients. Male versus female sex
was self-reported by veterans. Race was also self-reported, and
categorized as white, black, or other (14). We identiﬁed
comorbid illnesses using a combination of inpatient hospital
discharge diagnoses, outpatient diagnoses, physician problem
lists, procedures, and laboratory results (Online Appendix).
We applied validated algorithms to deﬁne the following
comorbidities: hypertension, diabetes, coronary artery dis-
ease, congestive heart failure, chronic lung disease, smoking,
alcoholism, hyperthyroidism, and hypothyroidism (15–18).
Clinical measures were also included in the analytical models
and included body mass index, kidney function by estimated
glomerular ﬁltration rate (eGFR), and proteinuria dipstick.
Baseline characteristics were deﬁned if ever diagnosed before
or at the time subjects entered the study, and all covariates
were time-updated during the follow-up period.
Statistical analysis. We initially compared baseline char-
acteristics of participants who eventually did and did not
develop incident AF. Normally distributed continuous
variables were expressed as means and standard deviations
and were compared by unpaired t tests, whereas continuous
variables not normally distributed were expressed as medians
and interquartile ranges (IQR), and were compared by the
Wilcoxon rank sum test. Categorical variables were ex-
pressed as percentages and were compared by the chi-square
test. We compared incidence rates with 95% conﬁdence
intervals (CI) of AF, stratiﬁed by age and race and were
presented as number of events per 1,000 person-years. We
obtained estimates of relative risk using a time-to-event
analysis with multivariable Cox proportional hazards
regression models including demographic and traditional
risk factors, as well as markers of HIV severity (CD4þ cell
count and viral load). To determine which covariates to
include in the ﬁnal multivariate models, likely predictors and
confounders were speciﬁed a priori and included for face
Figure 1 Incidence Rates of AF Among HIV-Infected Veterans, Stratiﬁed by Age and Race
Error bars represent 95% conﬁdence intervals. AF ¼ atrial ﬁbrillation; HIV ¼ human immunodeﬁciency virus.
Hsu et al. JACC Vol. 61, No. 22, 2013
Incident Atrial Fibrillation in the HIV-Infected June 4, 2013:2288–95
2290validity. Other candidate covariates were included in the
multivariate models if they were associated with either the
primary predictors of interest or the outcome of AF from
general clinical knowledge and data from prior studies. In
our ﬁnal model, we adjusted for demographic characteristics,
markers of HIV disease severity (CD4þ cell count and HIV
RNA viral load), comorbidities (hypertension, diabetes,
coronary artery disease, congestive heart failure, chronic lung
disease, smoking, alcoholism, hyperthyroidism, and hypo-
thyroidism), and clinical measures (body mass index, eGFR,
and proteinuria). We assessed the proportional hazards
assumption using the Schoenfeld test and by comparing
plots of log (log[survival]) versus log of survival time. A
missing indicator variable was included to retain observa-
tions for missing data in our ﬁnal multivariable models,
unless this caused violation of the proportional hazards
assumption. Analyses were performed using Stata version
11.0 (StataCorp, College Station, Texas).
Results
Baseline characteristics. Of the 30,533 HIV-infected
veterans who comprised the study cohort, we identiﬁed 780
(2.6%) patients who developed AF over a median duration of
HIV infection and follow-up of 6.8 years (IQR: 2.9 to 11.2),
which amounted to a total of 214,012 person-years of obser-
vation. These events comprised 641 diagnoses of AF, and
139 of atrial ﬂutter. There were 60 patients who had both AF
and atrial ﬂutter during follow-up. Among patients who
developed AF, 68% (534 of 780) were hospitalized for an
alternative reason before the diagnostic AF event. There were
7,163 total deaths during the follow-up period. The overall
incidence rate of AF in our cohort was 3.6 events per 1,000
person-years (95% CI: 3.4 to 3.9); however, we also stratiﬁedoverall AF incidence rates by age and race (Fig. 1). The crude
incidence of AF increased with age, and was 15-fold higher
in patients 65 years of age (15.5 events per 1,000 person-
years; 95% CI: 13.0 to 18.5) compared with those younger
than 35 years of age (1.1 events per 1,000 person-years; 95%
CI: 0.8 to 1.5). Among patients age <45 years, blacks and
whites had similar rates of AF. By contrast, among those
age 45 years, blacks had consistently lower rates of AF.
At baseline, patients who went on to develop incident AF
were older, and more likely to be white and to have traditional
AF risk factors, including hypertension, diabetes, coronary
artery disease, heart failure, overweight/obesity, reduced eGFR,
and proteinuria (Table 1). Among those diagnosed with AF,
the CHADS2 score at diagnosis was 0 in 32.3%, 1 in 37.2%,
2 in 18.3%, 3 in 9.2%, 4 in 2.4%, and 5 in 0.5%. Throughout
follow-up, we analyzed a median of 31 (IQR: 0 to 73)
measurements of CD4þ cell count per subject, and a median
of 57 (IQR: 13 to 109) total measurements of HIV viral load
per subject. Baseline median CD4þ cell count and viral load
were similar among veterans who did and did not develop AF.
Association between markers of HIV disease severity
with incident AF. In this HIV-infected cohort, overall,
there was a signiﬁcant association between worsened HIV
disease severity as measured by time-updated CD4þ cell
count and HIV RNA viral load and the risk of AF.
Lower CD4þ cell count (<200 cells/mm3 compared with
>350 cells/mm3) and higher HIV RNA viral load
(>100,000 copies/ml compared with <500 copies/ml) were
independently associated with 40% and 70% higher risks of
AF, respectively, in models that adjusted for demographic
characteristics, time-updated comorbidities, and time-
updated clinical measurements (Table 2). We performed a
subanalysis stratiﬁed by age at baseline (<50 years and
Table 1
Baseline Characteristics of 30,533 HIV-Infected Persons With and Without Incident AF
During Follow-Up
Characteristic
No Atrial Fibrillation
(n ¼ 29,753)
Incident Atrial Fibrillation
(n ¼ 780) p Value
Demographics
Age, yrs 46.9  10.8 53.6  11.4 <0.001
Female 2.8 1.7 0.051
Race* <0.001
White 44.6 55.2
Black 54.1 43.8
Other 1.3 1.0
Markers of HIV disease severity
CD4 count, cells/mm3 343 (153–560) 321 (149–541) 0.220
HIV viral load, copies/ml 10,743 (400–835,000) 9,140 (400–90,467) 0.573
Comorbidities
Hypertension 16.7 35.1 <0.001
Diabetes 3.6 6.7 <0.001
Coronary artery disease 1.5 3.7 <0.001
Congestive heart failure 0.8 3.9 <0.001
Chronic lung disease 3.1 3.1 0.964
Previous stroke 0.4 0.5 0.437
Smoking 9.4 8.0 0.160
Alcoholism 7.4 7.2 0.835
Hyperthyroidism 1.5 1.4 0.929
Hypothyroidism 0.8 1.5 0.018
Clinical measures
Body mass index, kg/m2 0.010
<18.5 4.1 3.7
18.5–24.9 45.7 47.5
25.0–29.9 34.2 27.5
30.0 16.0 21.4
Kidney function, eGFR, ml/min/1.73 m2 <0.001
60 92.8 86.0
30–59 5.4 10.7
<30 1.9 3.3
Proteinuria, urine dipstick, mg/dl <0.001
0 64.5 55.4
30 25.3 31.2
100 6.1 6.4
300 3.4 4.4
2,000 0.7 2.7
Medications
Any antihypertensive agent 9.8 19.6 <0.001
Statin 2.0 3.1 0.026
Values are mean  SD, %, or median (IQR). *Proportions for race exclude patients with missing race data, which occurred in 7,438 (25.0%) patients
in the no atrial ﬁbrillation category, and 148 (19.0%) patients in the atrial ﬁbrillation category.
AF ¼ atrial ﬁbrillation; eGFR ¼ estimated glomerular ﬁltration rate; HIV ¼ human immunodeﬁciency virus; IQR ¼ interquartile range.
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229150 years). This analysis suggested that a higher HIV
RNA viral load (>100,000 copies/ml compared with
<500 copies/ml) was associated with an increased risk of
AF in both younger (hazard ratio [HR]: 1.9; 95% CI: 1.2
to 3.1; p ¼ 0.007) and older (HR: 1.6; 95% CI: 0.9 to 2.6;
p ¼ 0.081) patients. Although the association appeared to
be somewhat weaker in the older age group, there was no
statistically signiﬁcant difference in the association of
HIV viral load with AF in the 2 age groups (test for
interaction: p ¼ 0.817). Similarly, we observed the associa-
tion of low CD4þ count (<200 cells/mm3 compared with>350 cells/mm3) with AF to be equivalent in both younger
(HR: 1.3; 95% CI: 0.9 to 2.0; p¼ 0.158) and older (HR: 1.4;
95% CI: 1.0 to 2.0; p ¼ 0.062) participants (test for interac-
tion: p ¼ 0.935).
In exploratory analysis of patients who only developed
AF (excluding those with atrial ﬂutter), we found a similar
association between markers of HIV disease severity and
development of AF. After adjustment, a higher HIV
RNA viral load (>100,000 copies/ml compared with <500
copies/ml) was signiﬁcantly associated with an increased
risk of AF (HR: 1.6; 95% CI: 1.1 to 2.4; p ¼ 0.011), and a
Table 2
Association of Patient Characteristics With Incident AF After Multivariable Adjustment
in HIV-Infected Persons
Demographic Adjusted
Hazard Ratios for AF*
(95% CI) p Value
Multivariable Adjusted
Hazard Ratios for AFy
(95% CI) p Value
Demographics
Age, yrs
<35 Reference d Reference d
35–44 1.7 (1.2–2.5) 0.004 1.3 (0.8–2.0) 0.250
45–54 3.5 (2.5–4.9) <0.001 2.4 (1.6–3.6) <0.001
55–64 8.1 (5.7–11.6) <0.001 4.7 (3.1–7.1) <0.001
65 14.9 (10.2–21.5) <0.001 7.9 (5.1–12.3) <0.001
Female 1.0 (0.6–1.7) 0.958 1.1 (0.6–2.1) 0.663
Race
White Reference d Reference d
Black 0.8 (0.7–0.9) 0.001 0.6 (0.5–0.7) <0.001
Other 0.7 (0.3–1.5) 0.351 0.7 (0.3–1.6) 0.344
Markers of HIV disease severity
CD4þ cell count, cells/mm3
>350 Reference d Reference d
200–350 1.0 (0.8–1.3) 0.768 1.1 (0.8–1.4) 0.714
<200 1.6 (1.3–2.0) <0.001 1.4 (1.1–1.8) 0.018
HIV RNA viral load, copies/ml
<500 Reference d Reference d
500–29,999 0.9 (0.8–1.1) 0.496 1.0 (0.8–1.3) 0.807
30,000–100,000 1.2 (0.9–1.6) 0.248 1.2 (0.9–1.7) 0.223
>100,000 1.8 (1.4–2.4) <0.001 1.7 (1.2–2.4) 0.002
Comorbidities
Hypertension 1.7 (1.5–2.0) <0.001 1.1 (1.0–1.3) 0.156
Diabetes 1.9 (1.6–2.3) <0.001 1.2 (1.0–1.4) 0.134
Coronary artery disease 4.7 (4.0–5.5) <0.001 2.4 (2.0–2.9) <0.001
Congestive heart failure 9.3 (7.9–10.9) <0.001 4.8 (3.9–5.9) <0.001
Chronic lung disease 1.9 (1.6–2.3) <0.001 1.1 (0.9–1.4) 0.238
Smoking 1.5 (1.3–1.7) <0.001 1.0 (0.8–1.1) 0.578
Alcoholism 1.7 (1.5–2.0) <0.001 1.4 (1.1–1.7) 0.001
Hyperthyroidism 1.7 (1.4–2.2) <0.001 1.0 (0.8–1.4) 0.858
Hypothyroidism 2.2 (1.7–2.9) <0.001 1.5 (1.1–2.0) 0.010
Clinical measures
Body mass index, kg/m2
<18.5 Reference d Reference d
18.5–24.9 1.4 (1.0–2.0) 0.026 1.2 (0.9–1.7) 0.277
25.0–29.9 0.8 (0.7–1.0) 0.063 0.9 (0.7–1.1) 0.244
30.0 1.2 (1.0–1.5) 0.060 1.1 (0.9–1.4) 0.422
Kidney function, eGFR, ml/min/1.73 m2
60 Reference d Reference d
30–59 1.6 (1.3–1.9) <0.001 1.1 (0.8–1.4) 0.654
<30 3.6 (2.7–4.8) <0.001 1.7 (1.2–2.4) 0.006
Proteinuria, urine dipstick, mg/dl
0 Reference d Reference d
30 1.7 (1.4–2.0) <0.001 1.5 (1.2–1.8) <0.001
100 2.2 (1.7–2.9) <0.001 1.4 (1.0–2.0) 0.033
300 3.2 (2.3–4.4) <0.001 1.7 (1.1–2.5) 0.011
2,000 5.5 (3.5–8.6) <0.001 2.5 (1.5–4.3) 0.001
Female sex was not signiﬁcantly associated with atrial ﬁbrillation in multivariate modeling, but was included in the model for face validity.
*Demographic adjusted models control for age, sex, and race. yMultivariable adjusted models control for age, sex, race, and time-updated CD4þ
cell count, HIV RNA viral load, hypertension, diabetes, coronary artery disease, congestive heart failure, chronic lung disease, smoking, alcoholism,
hyperthyroidism, hypothyroidism, body mass index, estimated glomerular ﬁltration rate, and proteinuria.
CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁltration rate; other abbreviations as in Table 1.
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2293lower CD4þ cell count (<200 cells/mm3 compared with
>350 cells/mm3) had a nonsigniﬁcant association with
increased AF risk (HR: 1.3; 95% CI: 0.9 to 1.7; p ¼ 0.106).
Because patients with worsened HIV disease severity may
more often utilize healthcare, we performed exploratory
analyses that adjusted for the number of annual outpatient
visits as well as number of annual inpatient hospitalizations.
After adjustment for the number of annual outpatient
visits in the original multivariable model, both a higher
HIV RNA viral load (>100,000 copies/ml compared
with <500 copies/ml; HR: 1.8; 95% CI: 1.3 to 2.5; p ¼
0.001), and a lower CD4þ cell count (<200 cells/mm3
compared with>350 cells/mm3;HR: 1.3; 95%CI: 1.0 to 1.8;
p ¼ 0.030) remained associated with an increased risk of
AF. After adjustment for the number of annual inpatient
hospitalizations in the original multivariable model, a higher
HIV RNA viral load (>100,000 copies/ml compared
with <500 copies/ml) continued to be associated with an
increased risk of AF (HR: 1.4; 95%CI: 1.0 to 2.0; p¼ 0.036),
whereas the association of AF with a lower CD4þ cell count
(<200 cells/mm3 compared with >350 cells/mm3) was
attenuated somewhat and was no longer statistically signiﬁ-
cant (HR: 1.2; 95% CI: 0.9 to 1.6; p¼ 0.181). In a sensitivity
analysis, we investigated the association between HIV disease
severity and the risk of AF after excluding events from patients
diagnosed with a single, isolated inpatient AF episode (n ¼
115 exclusive of 780 with AF). After multivariable adjust-
ment, a higher HIV RNA viral load (>100,000 copies/ml
compared with <500 copies/ml) continued to be associated
with an increased risk of AF (HR: 1.7; 95%CI: 1.1 to 2.4; p¼
0.009), whereas a lower CD4þ cell count (<200 cells/mm3
compared with >350 cells/mm3) showed little association
with AF risk (HR: 1.1; 95% CI: 0.8 to 1.5; p ¼ 0.547).
Risk factors associated with incident AF. In demographic
adjusted analyses, we found that markers of HIV disease
severity, comorbidities, and clinical measures were all sig-
niﬁcantly associated with incident AF (Table 2). In models
that adjusted for demographic characteristics, time-updated
comorbidities, and time-updated clinical measurements,
there was a progressive increase in the incidence of AF with
increasing age decades; compared with those age <35 years,
those 65 years had an approximate 8-fold increase in the
adjusted risk of AF. Overall, blacks had an approximate
40% reduction in the adjusted risk of AF compared with
whites. As seen in Table 2, HIV-infected persons with
cardiovascular comorbidities including coronary artery
disease and congestive heart failure had adjusted 2.4-fold
and 4.8-fold increased risk of AF, respectively. Additional
risk factors associated with an increased risk of AF after
multivariable adjustment included alcoholism, hypothy-
roidism, kidney disease, and proteinuria.
Discussion
In a large, national sample of HIV-infected veterans
receiving care in the Veterans Health Administration, weobserved a signiﬁcant and graded association between
markers of HIV severity and incident AF. Importantly, both
a lower CD4þ cell count and a higher viral load assessed by
multiple, time-updated measures provided complementary
and independent prognostic information, with an overall
pattern of worsened HIV disease severity corresponding
with an increased risk of incident AF. It is of note that
CD4þ cell count and viral load were similar at baseline in
those who did and did not go on to develop AF, suggesting
a more direct role of HIV severity in the development of AF.
Nonetheless, traditional AF risk factors including increased
age, white race, coronary artery disease, congestive heart
failure, alcoholism, proteinuria, and reduced kidney function
were also strongly and independently associated with
increased AF risk in the setting of HIV. To our knowledge,
this is the ﬁrst and only study to evaluate AF incidence in
HIV-infected individuals, and to establish a biologically
plausible association of markers of HIV severity with incident
AF. Our results are clinically meaningful because they are the
ﬁrst to explore incidence rates of AF in the HIV-infected,
and the ﬁrst to suggest that HIV infection severity may be
directly linked with the risk of developing AF.
Although there are no previously reported studies exam-
ining the association of HIV infection and AF, other studies
have found that HIV-infected individuals have higher than
expected risk for a number of age-related conditions,
including cardiovascular disease, certain types of cancer,
osteoporosis, and kidney disease. Potential mechanisms may
involve changes to the adaptive immune system seen in the
very old (“immunosenescence”) and may potentially be
related to persistent inﬂammation (19,20). Because both
advanced age and inﬂammation have been implicated in an
increased risk for the development of AF in previous studies,
an association of HIV and AF could share similar mecha-
nisms (21,22). In our study, the associations of HIV viral
load and CD4þ cell count with AF were somewhat atten-
uated after controlling for the number of hospitalizations,
suggesting that the association is potentially mediated by the
severity of illness and its attendant inﬂammatory state.
Overall, in an HIV-infected population, our study found
that older age predicted a consistently rising risk of AF
development. In Table 3, we compare age-stratiﬁed crude
incidence rates of AF in our HIV-infected cohort with
previously published reports in large epidemiological studies
fromManitoba (23), theAtherosclerosisRisk inCommunities
study (24), Framingham (25), Rotterdam (26), and Olmsted
County, Minnesota (27). Our HIV cohort had higher repre-
sentation of the younger age strata (patient age <65 years)
due to the demographics of HIV-infected veterans. Crude
incidence rates of AF were much higher among these younger
HIV-infected patients in our study compared with
community-living individuals without HIV reported in these
other community-based studies. Our rates were even more
striking because the comparison studies included fewer persons
of African descent, who have lower AF risk, whereas blacks
comprised approximately one-half of our cohort. These
Table 3 Incident Rates of AF in Comparison to 5 Previous Large, Population-Based Studies
Age Group
(yrs)
VA Clinical Case
Registry HIV Study
Manitoba
Study
Atherosclerosis
Risk in Communities
Study*
Framingham
Study*
Rotterdam
Study*
Olmsted
County Study*
<35 1.1 d d d d d
35–44 1.8 w0.1–0.25 d d d d
45–54 3.7 w0.5–0.8 0.7–2.3 d d d
55–64 8.7 w2.3–3.7 1.4–5.8 3.1 2.2 4.3
65–74 15.5y w5.3–8.5 5.8–12.3 w9.0 9.9 12.9
75–84 w10.5 10.9–21.0z w18.0 21.9 24.5
85 16.9 41.1–47.5x 38.0 25.4 39.7
Values are incidence rate per 1,000 person-years. *Data represent incidence rates among men only in each study to provide an appropriate
comparison to the male predominated population in the VA Clinical Case Registry HIV study. yRepresents 65-year category. zRepresents 75- to
79-year category. xRepresents 80-year category.
VA ¼ Veterans Affairs; other abbreviations as in Tables 1 and 2.
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2294ﬁndings are suggestive, but not conclusive, of an increased
incidence of AF in HIV-infected individuals, including
younger patients, which can only be fully evaluated in future
studies that include a non–HIV-infected comparison group.
In our study, both CD4þ cell count and HIV RNA viral
load were independently associated with an increased risk of
AF. These associations were only modestly attenuated after
adjusting for traditional risk factors, suggesting a strong
association that was not overtly confounded by the traditional
risk factors included in our multivariate models. Low CD4þ
cell counts seen inHIV-infected persons may have similarities
to age-associated immunologic changes seen in HIV-
uninfected older patients marked by defects in T-cell regen-
erative potential and loss of immunoregulatory function (28).
In previous studies, a low CD4þ T-cell count has been asso-
ciated with early-onset age-associated diseases, potentially by
a contribution of immunosenescence, persistent immunode-
ﬁciency, and inﬂammation (19). A high HIV RNA viral load
has been associated with persistently high levels of inﬂam-
mation, as deﬁned by levels of inﬂammatory cytokines such as
interleukin-6, C-reactive protein, and ﬁbrinogen, among
others (29,30). Many of these inﬂammatory markers decline
with antiretroviral therapy, suggesting that active HIV repli-
cation is either directly or indirectly responsible for this
inﬂammatory response.Because similar inﬂammatorymarkers
have been associated with AF (22,31), it is possible that viral
replication itself may be associated with increased AF risk,
potentially through an inﬂammatory mechanism that has yet
to be elucidated. In general, our ﬁndings merit future studies
investigating speciﬁc mechanisms by which HIV infection
may lead to development of AF in affected individuals.
Our ﬁndings raise important questions for the clinical
management of AF in the HIV-infected population. Al-
though our ﬁndings suggest that HIV-infected individuals
may be at higher risk of AF, particularly those with severe
HIV disease, we do not yet know whether AF is associated
with stroke, heart failure, or death in these populations.
Many previous studies have shown a marked reduction in the
risk of stroke with prescription of oral anticoagulation in AF
patients with speciﬁc risk factors (32,33). These studies, in
general, did not speciﬁcally include HIV patients; therefore,whether the same risk factors predispose HIV-infected
patients to stroke, and whether oral anticoagulation reduces
the risk of stroke in this population, remain to be investigated.
Study limitations. First, our cohort comprised HIV-
infected individuals only, without a speciﬁc noninfected
comparison group. The VA Clinical Case Registry is a well-
developed disease registry, but it does not include uninfected
controls. However, this is the ﬁrst study to examine AF
incidence in an HIV-infected cohort, and should be
considered an important step in deﬁning a possible link of
HIV-infection with risk of AF. Future studies should include
uninfected controls in order to enable a direct comparison of
AF risk. Second, our ﬁndings may not be generalizable to
speciﬁc populations poorly represented in our cohort, such as
women, nonveterans, or HIV-infected persons without
access to medical care. Third, although we adjusted for
a number of potential clinical factors associated with both
HIV-infection severity and AF, residual confounding is still
possible. In particular, patients who went on to develop AF
had more comorbid conditions, and we cannot exclude the
possibility that additional unknown confounding variables
not included in multivariable adjustment may account for
some or all of the associations we found. Fourth, veterans
with more severe HIV infection may be more likely to seek
medical care or have screening tests such as an electrocar-
diogram. Therefore, we cannot rule out the possibility that
detection bias accounted for some or all of the association we
found between lower CD4þ cell count and higher viral load
with higher risk of AF. Fifth, although previous studies have
conﬁrmed excellent sensitivity and speciﬁcity using ICD-9
codes for AF diagnoses (11), we were not able to conﬁrm
AF or atrial ﬂutter diagnoses in our study by over-reading of
electrocardiograms or telemetry strips because this informa-
tion was not available in the VA Clinical Case Registry.
Finally, we did not study antiretroviral therapy as a predictor
of incident AF in this HIV-infected cohort. We focused on
markers of HIV-infection severity as the ﬁrst step in sug-
gesting a link between HIV-infection and AF, which may or
may not reﬂect antiretroviral treatment. Future studies should
investigate the complex interplay of speciﬁc drug treatment
for HIV and subsequent risk of incident AF.
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2295Conclusions
In a large, national sample of HIV-infected persons, markers
of HIV severity, including CD4þ cell count and HIV viral
load were associated with development of AF even after
adjustment for traditional risk factors. These ﬁndings
suggest a potential biological link between HIV infection
and risk of incident AF that should be the focus of addi-
tional studies comparing AF incidence and clinical out-
comes in the HIV infected versus the HIV uninfected. In
HIV-infected individuals, future research should evaluate
mechanisms by which HIV disease severity increases AF
risk, whether AF is associated with an increased risk of
stroke, heart failure, and death, and whether or not oral
anticoagulation improves outcomes in this population.
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APPENDIX
For criteria to deﬁne outcomes and comorbid illnesses based on previous
published work, please see the online version of this article.
